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Aim: Asymmetric dimethylarginine (ADMA) is the major endogenous inhibitor of nitric oxide synthase. We aimed to investigate the
ADMA levels in allergic rhinitis (AR) and nasal polyposis (NP).
Materials and methods: A total of 29 AR patients, 21 NP patients, and 30 healthy subjects to be used as a control group were enrolled in
the study. ADMA was measured in the AR, NP, and control groups with enzyme-linked immunosorbent assay. Any patients or control
subjects with coronary artery disease, renal failure, diabetes mellitus, or hypertension were excluded from the study.
Results: The mean ADMA serum concentration was 0.52 ± 0.08 µmol/L in the AR group, 0.62 ± 0.10 µmol/L in the NP group, and 0.67
± 0.09 µmol/L in the control group. The ADMA serum concentration in the AR group was significantly lower than in the control group
(P < 0.001). Considered together, the NP and AR groups had ADMA levels that were significantly lower than in the control group (P <
0.001).
Conclusion: In the present study, lower ADMA levels were found in the AR and NP groups.
Key words: Asymmetric dimethylarginine, allergic rhinitis, nasal polyposis

1. Introduction
Allergic rhinitis (AR), encountered particularly in
industrialized countries, is increasing in prevalence and
is an important health problem affecting the quality of
life for affected people (1). Immunoglobulin E-mediated
inflammatory response plays an important role in the
formation of AR. This inflammatory response is triggered
by various allergens in the nasal mucosa. Various
mediators such as chemokines and cytokines released
from eosinophils, basophils, T cells, and mast cells play a
role in this formation. This local inflammation may trigger
systemic inflammation (2).
Nasal polyposis (NP) is a chronic inflammatory disease
of the nasal mucosa and upper respiratory tract (3). The
etiology and pathogenesis of NP are still unclear, but it is
seen in a variety of disease states such as infection, allergy,
asthma, and aspirin hypersensitivity (4,5).
Nitric oxide (NO) has various roles in the upper
airway physiology. NO is an endogenous free radical gas
mediator of fundamental importance in the regulation of
vascular tone, host defense, inflammation, coagulation,
and neurotransmission (6). In addition to these, it has
been reported that NO may be used as a marker in the
diagnosis of esophageal cancer (7). NO has been measured
* Correspondence: mehmet_tosun @yahoo.com

in the upper respiratory tract and tends to be elevated in
inflammatory disorders such as AR (8,9). Asymmetric
dimethylarginine (ADMA) is an endogenous inhibitor
of nitric oxide synthase (NOS) (10). ADMA may play a
role in inflammatory airway diseases such as asthma (11).
ADMA has been shown to affect airway physiology and
collagen formation in the airways of mice by altering the
L-arginine metabolizing pathways (12). ADMA levels
were also found to be increased in human asthma lung
and sputum samples (13). However, the similar pathogenic
features of NP and ADMA are not yet known.
In the present study, we aimed to compare ADMA
levels in patients with AR and NP who did not have any
cardiovascular risk markers like diabetes, hypertension,
coronary artery disease, or renal disease to the ADMA
levels in control subjects without AR or NP.
2. Materials and methods
2.1. Study population
The total study population consisted of 81 subjects: 29
of them were patients with AR, 21 of them were patients
with NP, and 30 of them were healthy controls. All
patients were informed about the study, and informed
consent was obtained. The study was approved by the
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3. Results
There were 29 patients in the AR group, 21 patients in the
NP group, and 30 healthy subjects in the control group.
The mean ages of the groups were 37.3 ± 12.5 years, 42.2
± 12.1 years, and 35.9 ± 14.4 years, respectively. The mean
ages were similar among groups (P = 0.354). The mean
ADMA serum concentration was 0.52 ± 0.08 µmol/L in
the AR group, 0.62 ± 0.10 µmol/L in the NP group, and
0.67 ± 0.09 µmol/L in the control group. The ADMA
serum concentration was significantly higher in the NP
group than in the AR group (P = 0.001). ADMA serum
concentration was significantly lower in the AR group
than in the control group (P < 0.001). ADMA serum
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concentrations were lower in the NP group than in the
control group, but this trend did not reach statistical
significance (P = 0.069). When the NP and AR groups were
considered together, the ADMA levels were significantly
lower than in the control group (P < 0.001). The Figure
shows the groups’ ADMA serum levels.
4. Discussion
ADMA is a NOS inhibitor. Human neuronal NOS (nNOS),
inducible (iNOS), and endothelial (eNOS) are types of
NOS. The relationship between the increase in ADMA
levels and endothelial dysfunction has been established
clearly. ADMA level has also been found to be influential
in diabetes mellitus, chronic renal failure, metabolic
syndrome, and Behçet’s disease (14–16).
AR is an allergic reaction, expressed as inflammation
in the nasal mucosa. Studies have reported that increased
oxidant stress and antioxidant mechanism deficiencies
may play a role in the pathophysiology of AR (17,18). In
several studies, it has been reported that there is a high
level of NOS associated with AR. This condition may be
connected to a low or normal level of ADMA. High levels
of iNOS have been found in AR patients, but eNOS levels
were not found to be significantly different in AR patients
(19,20). Similarly, Chiba et al. found higher levels of iNOS
in their experimental study. They found no significant
difference in the levels of eNOS and nNOS. They reported
that excess iNOS may have a role in the pathophysiology
of AR (21). The low ADMA levels that we found in the
AR group support the description of this relationship. Li
et al. supported this view by reporting increased iNOS and
nNOS in AR patients (22).
Increased levels of NOS in AR patients may also suggest
increased NO levels. In several studies, as expected, NO
was higher in patients with AR than in the control group
(23,24). Ciprandi et al. reported that the amount of NO
directly increases with exposure to allergens (25). ADMA

ADMA (µmol/L)

Ethics Committee of Abant İzzet Baysal University.
Patients and control subjects were selected to participate
in the study from the otorhinolaryngology outpatient
clinics at our hospital. A whole physical examination was
performed, and a thorough clinical history was taken from
each patient. AR diagnosis was made mainly by clinical
history. NP was diagnosed mainly by nasal examination
with a lighted instrument or, rarely, with the aid of nasal
endoscopy or paranasal computerized tomography.
Subjects in the control group were selected from persons
without a history of nasal disease or allergies. Any patients
or control subjects with diabetes, hypertension, coronary
artery disease, or renal disease were excluded from the
study.
2.2. Laboratory analysis
Venous blood samples were obtained from each participant
in the morning following a 12-h fasting period. Blood
samples were centrifuged 30 min after collection at 2750
× g for 10 min, and the supernatant plasma was then
transferred into polypropylene tubes at –80 °C until the
assays were determined. The plasma levels of ADMA were
measured by the enzyme-linked immunosorbent assay
(ELISA) method. Plasma ADMA levels were determined
using a commercial ELISA kit (Immundiagnostik AG,
Bensheim, Germany).
Other biochemical parameters such as fasting glucose,
lipid profile, renal function tests, hepatic function tests,
and complete blood counts were analyzed with standard
laboratory methods using commercially available kits.
2.3. Statistical analysis
SPSS 15.0 (SPSS Inc., Chicago, IL, USA) was used for
the statistical calculations. Data are shown as mean ±
standard deviation or median for continuous variables
and frequencies and percentages for categorical variables.
Comparisons between the groups were performed using
one-way ANOVA for the continuous variables and the
Kruskal–Wallis test for the categorical variables. Subgroup
analysis was made using Student’s t-test. P < 0.05 was
considered statistically significant.
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Figure. The study groups’ ADMA serum levels.
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levels in our AR patient group were significantly lower
than in the control group. ADMA levels may be associated
with the pathophysiology of AR and also may be related to
allergic conditions.
Allergic processes may play an important role in
the formation of NP. An increase in oxidative stress and
deficient antioxidant mechanisms may also play a role in
the pathophysiology of NP (26,27). Several studies have
reported increased NOS levels in NP patients (28,29). We
also found lower ADMA values in the NP group than in
the control group, but there was no statistically significant
difference. This may be due to the limited number of
patients in the NP group.
Yoshimura et al. reported that NOS and NO may
trigger some allergic-based diseases (30). The relationship
between the phagocytic myeloperoxidase system and NO
has been established clearly. However, increases in cases

of allergic mechanisms have not been clearly confirmed.
In both the NP and AR groups, ADMA levels were
significantly lower than in the control group. There may
be a relationship between decreased ADMA levels and
increased NOS and NO levels.
The present study is the first investigation of the
relationship between ADMA levels and the allergy-based
diseases AR and NP. Based on our results, increased NOS
and NO levels in allergic states may indicate a possible
relationship with ADMA. However, to more clearly
confirm the relationship between ADMA and NOS and
NO in these allergic diseases, more studies are needed.
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